FDA Lifts Clinical Hold on Aardvark Therapeutics’ ARD-101
Aardvark Therapeutics said the FDA lifted the clinical hold on ARD-101, allowing clinical development for hyperphagia in Prader-Willi Syndrome to potentially resume.
Aardvark Therapeutics said the FDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi Syndrome, allowing clinical development to potentially resume.Key Highlights:Original SEC Filing: Aardvark Therapeutics, Inc. [ AARD ] - 8-K - Oct. 22, 2026This is an AI-powered summary. It may co…